Business Context and Reporting Period
This Form 8-K was filed by Greatbatch, Inc. on December 16, 2013. The report details a strategic corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses on a regulatory filing event rather than financial performance data.
Material Changes
On December 16, 2013, Greatbatch, Inc. filed a Pre-Market Approval (PMA) application with the U.S. Food & Drug Administration (FDA) for its spinal cord neuromodulation system designed to treat chronic pain of the trunk and limbs. This action represents a material strategic shift toward developing complete medical device systems to enhance the company's growth and profitability profile.
Outlook and Management Commentary
Management indicates that this medical device strategy is being executed through the company's subsidiary, QiG Group. The initiative leverages Greatbatch's existing intellectual property and discrete technologies to expand its product offerings beyond its traditional scope.
Investor Verification Points
- Confirm the status and timeline of the FDA Pre-Market Approval (PMA) process for the spinal cord neuromodulation system.
- Verify the operational role and capabilities of the QiG Group subsidiary in executing this new strategy.
- Assess the potential capital requirements and timeline for commercialization of the new medical device system.
- Review subsequent filings for updates on the FDA application status or any related regulatory feedback.